BioCryst Pharmaceuticals Inc
BCRX7.320USD
+0.070+0.97%
Close 10/31, 16:00（ET）Quotes delayed by 15 min
1.54BMarket Cap
LossP/E TTM
More Details of BioCryst Pharmaceuticals Inc Company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BioCryst Pharmaceuticals Inc Info
Ticker SymbolBCRX
Company nameBioCryst Pharmaceuticals Inc
IPO dateMar 04, 1994
CEOMr. Charles K. Gayer
Number of employees580
Security typeOrdinary Share
Fiscal year-endMar 04
Address4505 Emperor Blvd Ste 200
CityDURHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code27703-8457
Phone19198591302
Websitehttps://www.biocryst.com/
Ticker SymbolBCRX
IPO dateMar 04, 1994
CEOMr. Charles K. Gayer
Company Executives of BioCryst Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
90.44K
+0.75%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
41.01K
+1.68%
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
90.44K
+0.75%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United States (Country)
140.34M
85.91%
Outside of U.S.
16.50M
10.10%
Other
6.52M
3.99%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
8.09%
Deerfield Management Company, L.P.
5.78%
Two Sigma Investments, LP
4.05%
State Street Investment Management (US)
4.04%
Other
68.31%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
8.09%
Deerfield Management Company, L.P.
5.78%
Two Sigma Investments, LP
4.05%
State Street Investment Management (US)
4.04%
Other
68.31%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.25%
Investment Advisor/Hedge Fund
28.94%
Hedge Fund
25.79%
Research Firm
6.43%
Individual Investor
1.19%
Pension Fund
1.00%
Bank and Trust
0.45%
Family Office
0.06%
Sovereign Wealth Fund
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
553
208.53M
99.05%
+5.29M
2025Q2
551
184.03M
87.67%
-16.63M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
20.50M
9.77%
-1.12M
-5.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
17.04M
8.12%
-849.42K
-4.75%
Jun 30, 2025
Deerfield Management Company, L.P.
12.17M
5.8%
+7.48M
+159.36%
Sep 12, 2025
Two Sigma Investments, LP
8.52M
4.06%
+3.25M
+61.72%
Jun 30, 2025
State Street Investment Management (US)
8.51M
4.05%
+691.99K
+8.86%
Jun 30, 2025
Kynam Capital Management LP
8.46M
4.03%
-464.78K
-5.21%
Jun 30, 2025
UBS Financial Services, Inc.
5.61M
2.67%
+3.21M
+133.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.05M
2.41%
+93.97K
+1.89%
Jun 30, 2025
Alkeon Capital Management LLC
4.76M
2.27%
-1.24M
-20.69%
Jun 30, 2025
Avoro Capital Advisors LLC
4.50M
2.14%
-4.20M
-48.28%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.75%
Invesco Biotechnology & Genome ETF
2.37%
Virtus LifeSci Biotech Products ETF
1.22%
ALPS Medical Breakthroughs ETF
0.95%
SPDR S&P Biotech ETF
0.72%
First Trust Small Cap Growth AlphaDEX Fund
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Direxion Daily S&P Biotech Bull 3X Shares
0.41%
AAM Sawgrass US Small Cap Quality Growth ETF
0.38%
First Trust Small Cap Core Alphadex Fund
0.24%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.75%
Invesco Biotechnology & Genome ETF
Proportion2.37%
Virtus LifeSci Biotech Products ETF
Proportion1.22%
ALPS Medical Breakthroughs ETF
Proportion0.95%
SPDR S&P Biotech ETF
Proportion0.72%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.53%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.41%
AAM Sawgrass US Small Cap Quality Growth ETF
Proportion0.38%
First Trust Small Cap Core Alphadex Fund
Proportion0.24%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
